Last reviewed · How we verify

Alpha1 Blocker

Eli Lilly and Company · FDA-approved active Small molecule

Alpha-1 blockers inhibit alpha-1 adrenergic receptors on vascular smooth muscle and the prostate, causing vasodilation and reduced urinary obstruction.

Alpha-1 blockers inhibit alpha-1 adrenergic receptors on vascular smooth muscle and the prostate, causing vasodilation and reduced urinary obstruction. Used for Hypertension, Benign prostatic hyperplasia with lower urinary tract symptoms.

At a glance

Generic nameAlpha1 Blocker
SponsorEli Lilly and Company
Drug classAlpha-1 adrenergic receptor antagonist
TargetAlpha-1 adrenergic receptor
ModalitySmall molecule
Therapeutic areaCardiovascular, Urology
PhaseFDA-approved

Mechanism of action

These drugs selectively block alpha-1 adrenergic receptors, which mediate vasoconstriction and smooth muscle contraction. By antagonizing these receptors, alpha-1 blockers reduce peripheral vascular resistance (lowering blood pressure) and relax smooth muscle in the prostate and bladder neck (improving urinary flow). This dual action makes them useful in both hypertension and benign prostatic hyperplasia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: